Utility of alpha peak frequency-based Brainmarker-I in antidepressant treatment stratification: Blinded out-of-sample validations for pharmacotherapy and brain stimulation
Helena Voetterl,
Alexander Sack,
Sebastian Olbrich,
Sven Stuiver,
Renee Rouwhorst,
Amourie Prentice,
Diego A. Pizzagalli,
Nikita van der Vinne,
Jeroen van Waarde,
Martin Brunovsky,
Martijn Arns
Affiliations
Helena Voetterl
Brainclinics Foundation, The Netherlands; Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands
Alexander Sack
Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands
Sebastian Olbrich
Department for Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Switzerland
Sven Stuiver
Rijnstate Hospital, Arnhem, The Netherlands
Renee Rouwhorst
neurocare clinics, Amsterdam & Den Haag, The Netherlands
Amourie Prentice
Brainclinics Foundation, The Netherlands
Diego A. Pizzagalli
Department of Psychiatry, Harvard Medical School, USA
Nikita van der Vinne
Synaeda Psycho Medisch Centrum, Drachten, The Netherlands
Jeroen van Waarde
Rijnstate Hospital, Arnhem, The Netherlands
Martin Brunovsky
National Institute of Mental Health, Klecany, Czech Republic
